Keytruda | pharmaphorum

Thursday 2 April 2026

Keytruda

News

Keytruda

Merck & Co's Keytruda shows potential in head and neck cance...

Merck & Co might be able to find another use for its immunotherapy Keytruda in first line head and neck cancer, after revealing promising phase 3 trial results.

News

Keytruda

FDA approves Keytruda in cervical cancer

Merck & Co’s blockbuster Keytruda has been approved in advanced second line cervical cancer, becoming the first drug in its class approved in the indication.

Views & Analysis

ASCO 2018 imagery

ASCO 2018 Preview – what to expect from this year’s conferen...

pharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the year for cancer medicine.

Partner Content

Immuno-Oncology Conference Kandeepan Ganeshalingam

Partner Content

Updates on Keytruda and future potential therapies advanceme...

SMi Group reports on preparations for SMi's inaugural Immuno-Oncology Conference, which is scheduled to take place 26 - 27 September in London.

News

Medical vials and Syringe, Isolated on Blue background

Moderna and Merck expand partnership to develop new cancer v...

Moderna and Merck & Co have expanded their partnership to develop and commercialise novel personalised messenger RNA (mRNA) cancer vaccines.

News

cancer-t-cells-16_9

Merck shows canny cancer strategy in $5.76bn Eisai milestone...

Firms will co-develop Lenvima and Keytruda combinations